ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

被引：0

作者：

Tina Kringelbach

Martin Højgaard

Kristoffer Rohrberg

Iben Spanggaard

Britt Elmedal Laursen

Morten Ladekarl

Charlotte Aaquist Haslund

Laurine Harsløf

Laila Belcaid

Julie Gehl

Lise Søndergaard

Rikke Løvendahl Eefsen

Karin Holmskov Hansen

Annette Raskov Kodahl

Lars Henrik Jensen

Marianne Ingerslev Holt

Trine Heide Oellegaard

Christina Westmose Yde

Lise Barlebo Ahlborn

Ulrik Lassen

机构：

[1] Rigshospitalet,Department of Oncology, Phase 1 Unit

[2] Aarhus University,Department of Molecular Medicine/Department of Oncology, Aarhus University Hospital, and Institute of Biomedicine, Pharmacology/Precision Medicine

[3] Aalborg University Hospital,Department of Oncology, Clinical Cancer Research Center

[4] Zealand University Hospital,Department of Clinical Oncology and Palliative Care

[5] University of Copenhagen,Department of Clinical Medicine, Faculty of Health and Medical Sciences

[6] Herlev Gentofte Hospital,Department of Oncology

[7] Odense University Hospital,Department of Oncology, Clinic of Precision Medicine

[8] University of Southern Denmark,Department of Clinical Research

[9] Vejle Hospital and University Hospital of Southern Denmark,Department of Oncology

[10] Vejle Hospital and University Hospital of Southern Denmark,Department of Clinical Genetics

[11] Aarhus University,Department of Oncology, Goedstrup Hospital, Goedstrup, and Department of Clinical Medicine

[12] Rigshospitalet,Center for Genomic Medicine

来源：

BMC Cancer | / 23卷

关键词：

Cancer genetics; Targeted therapies; Clinical trials; Cancer immunotherapy; Precision oncology; Tumor-agnostic therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
Kringelbach, Tina
Hojgaard, Martin
Rohrberg, Kristoffer
Spanggaard, Iben
Laursen, Britt Elmedal
Ladekarl, Morten
Haslund, Charlotte Aaquist
Harslof, Laurine
Belcaid, Laila
Gehl, Julie
Sondergaard, Lise
Eefsen, Rikke Lovendahl
Hansen, Karin Holmskov
Kodahl, Annette Raskov
Jensen, Lars Henrik
Holt, Marianne Ingerslev
Oellegaard, Trine Heide
Yde, Christina Westmose
Ahlborn, Lise Barlebo
Lassen, Ulrik
BMC CANCER, 2023, 23 (01)
[2] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Gautret, Philippe
Lagier, Jean-Christophe
Parola, Philippe
Van Thuan Hoang
Meddeb, Line
Mailhe, Morgane
Doudier, Barbara
Courjon, Johan
Giordanengo, Valerie
Vieira, Vera Esteves
Dupont, Herve Tissot
Honore, Stephane
Colson, Philippe
Chabriere, Eric
La Scola, Bernard
Rolain, Jean-Marc
Brouqui, Philippe
Raoult, Didier
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
[3] Bimatoprost versus clobetasol propionate in scalp alopecia areata: A prospective non-randomized open-label clinical trial
Bhusal, Mohan
Bhattarai, Sabina
Thapa, Binita
Shrestha, Prashanna R.
Sagar, G. C.
INDIAN DERMATOLOGY ONLINE JOURNAL, 2023, 14 (02) : 221 - 225
[4] RETRACTION: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Gautret, Philippe
Lagier, Jean-Christophe
Parola, Philippe
Hoang, Van Thuan
Meddeb, Line
Mailhe, Morgane
Doudier, Barbara
Courjon, Johan
Giordanengo, Valerie
Vieira, Vera Esteves
Dupont, Herve Tissot
Honore, Stephane
Colson, Philippe
Chabriere, Eric
La Scola, Bernard
Rolain, Jean-Marc
Brouqui, Philippe
Raoult, Didier
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2025, 65 (01)
[5] Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"
Wambier, Carlos Gustavo
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
[6] Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"
Saad, Mohamed O.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
[7] A PROSPECTIVE PHASE I/II OPEN LABEL, NON-RANDOMIZED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AMINOACT MULTI-KINASE INHIBITOR FOR THE ADJUVANT TREATMENT OF DOGS WITH SPONTANEOUSLY OCCURING CANCER
Ogilvie, G. K.
Chen, H. Y.
Mollstedt, O.
Proulx, D. M.
Van Horn, L.
Price, M. D.
Tsai, M. H.
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2011, 25 (03) : 746 - 746
[8] Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
Gupta, Abha A.
Tinker, Anna
Jonker, Derek
Jamal, Rahma
Hirte, Hal
Winquist, Eric W.
Chu, Quincy
Kollmannsberger, Christian
Wong, Ralph
Alcindor, Thierry
Nielsen, Torsten O.
Tsao, Ming
Cottrell, Tricia R.
Provencher, Diane
Hilton, John
Krzyzanowska, Monika K.
Elser, Christine
Hotte, Sebastien
Sederias, Joana
Zhang, Siwei
Dancey, Janet
ECLINICALMEDICINE, 2025, 79
[9] Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-DT): A multicenter, open-label, non-randomized, phase III clinical trial
Sangeeta Yadav
M. V. Manglani
D. H. Ashwath Narayan
S. Sharma
H. S. Ravish
Rohit Arora
V. Bosch Castells
S. Arya
P. Oster
Indian Pediatrics, 2014, 51 : 451 - 456
[10] Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-DT): A Multicenter, Open-label, Non-randomized, Phase III Clinical Trial
Yadav, Sangeeta
Manglani, M. V.
Narayan, D. H. Ashwath
Sharma, S.
Ravish, H. S.
Arora, R.
Castells, V. Bosch
Arya, S.
Oster, P.
INDIAN PEDIATRICS, 2014, 51 (06) : 451 - 456

← 1 2 3 4 5 →